Table 5.
Comparison of medical resource utilization and costs
| GT1 patients
|
GT3 patients
|
|||
|---|---|---|---|---|
| IFN-based treatment | IFN-free treatment (SOF/LDV) | IFN-based treatment | IFN-free treatment (SOF/DCV) | |
| Resource itema | ||||
| Liver clinic visits, mean ± SD | 12.5 ± 4.61 | 4.16 ± 0.37 | 10.5 ± 2.46 | 4.76 ± 1.58 |
| ER presentations, mean ± SD | 0.35 ± 0.86 | 0.01 ± 0.1 | 0.50 ± 0.97 | 0.02 ± 0.14 |
| Hospital admissions, mean ± SD | 0.07 ± 0.26 | 0 ± 0 | 0.10 ± 0.32 | 0 ± 0 |
| Blood tests, mean ± SD | 18 ± 9.07 | 4.18 ± 0.46 | 13.5 ± 5.56 | 4.78 ± 1.62 |
| Specialty referrals, mean ± SD | 0.80 ± 0.77 | 0.01 ± 0.10 | 0.60 ± 0.97 | 0 ± 0 |
| Costs (AUD)a | ||||
| Blood tests, mean ± SD | $1,946.97 ± 590.87 | $476.03 ± 8.41 | $1,555.69 ± 399.33 | $486.25 ± 27.91 |
| Other resources, mean ± SD | $147.81 ± 245.25 | $2.15 ± 21.49 | $168.89 ± 413.35 | $21.15 ± 43.88 |
| Initial specialist visit, mean ± SD | $129.60 ± 130.92 | $1.51 ± 15.09 | $105.89 ± 147.65 | $0 ± 0 |
| Antiviral drug costs, mean ± SD | $45,432.00 ± 13622.76 | $66,341.07 ± 0 | $11,972.09 ± 4,698.47 | $98,588.33 ± 33,353.83 |
| Total costs, mean ± SD | $47,656.39 ± 13,914.96 | $66,820.76 ± 42.57 | $13,802.06 ± 4,872.90 | $99,096.42 ± 33,422.64 |
Note:
a
Per patient.
Abbreviations: AUD, Australian dollars; DCV, daclatasvir; ER, emergency room; GT1, genotype 1; GT3, genotype 3; IFN, interferon; LDV, ledipasvir; SD, standard deviation; SOF, sofosbuvir.